Gallato Zirconium (IV) Phtalocyanine Complex Conjugated with SiO2 Nanocarrier as a Photoactive Drug for Photodynamic Therapy of Atheromatic Plaque.
Yuriy GerasymchukWojciech KałasJacek ArkowskiKarolina LedwaDariusz HreniakEdyta WysokińskaLeon StrządałaMarta ObremskaLarysa TomachynskiViktor Ya CherniiWiesław StrękPublished in: Molecules (Basel, Switzerland) (2021)
A new conjugate of gallato zirconium (IV) phthalocyanine complexes (PcZrGallate) has been obtained from alkilamino-modified SiO2 nanocarriers (SiO2-(CH2)3-NH2NPs), which may potentially be used in photodynamic therapy of atherosclerosis. Its structure and morphology have been investigated. The photochemical properties of the composite material has been characterized. in saline environments when exposed to different light sources Reactive oxygen species (ROS) generation in DMSO suspension under near IR irradiation was evaluated. The PcZrGallate-SiO2 conjugate has been found to induce a cytotoxic effect on macrophages after IR irradiation, which did not correspond to ROS production. It was found that SiO2 as a carrier helps the photosensitizer to enter into the macrophages, a type of cells that play a key role in the development of atheroma. These properties of the novel conjugate may make it useful in the photodynamic therapy of coronary artery disease.
Keyphrases
- photodynamic therapy
- reactive oxygen species
- coronary artery disease
- fluorescence imaging
- cancer therapy
- magnetic nanoparticles
- drug delivery
- cell death
- induced apoptosis
- dna damage
- room temperature
- cardiovascular disease
- cell cycle arrest
- percutaneous coronary intervention
- type diabetes
- emergency department
- signaling pathway
- cell proliferation
- endoplasmic reticulum stress
- adverse drug
- high resolution
- atrial fibrillation
- drug induced
- aortic stenosis
- high speed
- ejection fraction